• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Celsion Corporation (Amendment)

    2/11/22 6:10:51 AM ET
    $CLSN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLSN alert in real time by email
    SC 13G/A 1 clsn-sc13ga_123121.htm AMENDMENT TO SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1 )* 

     
    Celsion Corporation

    (Name of Issuer) 

     
    Common Stock, par value $0.01 per share
    (Title of Class of Securities)
     

     15117N503

    (CUSIP Number) 

     
    December 31, 2021
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☒ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    Page 2 of 9

     

    CUSIP No.    15117N503    

     

    1

    NAME OF REPORTING PERSONS
    Altium Capital Management, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2066653

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    0

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    0

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    0%

     
    12

    TYPE OF REPORTING PERSON

    IA, PN

     
             

     

     

     

     

     

    Page 3 of 9

     

    CUSIP No. 15117N503    

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth Fund, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2105101

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    0

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    0

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    0%

     
    12

    TYPE OF REPORTING PERSON

    PN

     
             

     

     

     

    Page 4 of 9

     

    CUSIP No. 15117N503    

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth GP, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2086430

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    0

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    0

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    0%

     
    12

    TYPE OF REPORTING PERSON

    OO

     
             

     

     

     

     

     

    Page 5 of 9

     

    CUSIP No. 15117N503    

     

    Item 1(a).   Name of Issuer:                                                          Celsion Corporation (the “Issuer”)
         
    Item 1(b).  

    Address of Issuer’s Principal Executive Offices:

    997 Lenox Drive, Suite 100
    Lawrenceville, New Jersey 08648

     

    Item 2(a).  

    Name of Person Filing:

    This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP (the “Fund”), Altium Capital Management, LLC, and Altium Growth GP, LLC. The Fund is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, the Fund. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, the Fund.

     

    Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

         
    Item 2(b).   Address of Principal Business Office or, if None, Residence:
        The address of the principal business office of each of the reporting persons is
    152 West 57 Street, FL 20, New York, NY 10019
         
    Item 2(c).   Citizenship:
        See Item 4 on the cover page(s) hereto.
         
    Item 2(d).   Title of Class of Securities:
        Common Stock, par value $0.01 per share
         
    Item 2(e).   CUSIP Number: 15117N503
         
    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
       
      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
                   

     

     

     

    Page 6 of 9

     

    CUSIP No. 15117N503    

     

      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
         
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
         
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           

      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           
    Item 4. Ownership.
     

     

    As of the close of business on December 31, 2021, each of the Reporting Persons had no beneficial ownership of the Issuer’s Common Stock. 

     

     

     

     

    Page 7 of 9

     

    CUSIP No . 15117N503    

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X]
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
    Item 10. Certification.
      Not applicable

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Dated: February 11, 2022  
         
      Altium Capital Management, LP  
         
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: CEO  
           
      Altium Growth Fund, LP  
         
      By: Altium Growth GP, LLC  
      Its: General Partner  
         
      Signature:   /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: Managing Member of Altium Growth GP, LLC  
           
      Altium Growth GP, LLC  
       
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: Managing Member  

     

     

     

     

    Page 8 of 9

     

    EXHIBIT INDEX

     

    EXHIBIT 1:  Joint Acquisition Statement Pursuant to Section 240.13d-1(k)

    Members of Group

     

     

     

     

    Page 9 of 9

     

    EXHIBIT 1

     

    JOINT ACQUISITION STATEMENT

    PURSUANT TO SECTION 240.13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.  The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate. 

     

      Dated: February 11, 2022  
         
      Altium Capital Management, LP  
         
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: CEO  
           
      Altium Growth Fund, LP  
         
      By: Altium Growth GP, LLC  
      Its: General Partner  
         
      Signature:   /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: Managing Member of Altium Growth GP, LLC  
           
      Altium Growth GP, LLC
       
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb  
      Title: Managing Member  
           

     

     

    Get the next $CLSN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLSN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CLSN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Celsion Corporation Announces Company Name Change to Imunon, Inc.

      New name reflects the evolution of the Company's business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage drug development company, today announced a company name change to Imunon, Inc., reflecting the evolution of the Company's business focus and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases. The Company's common stock will trade on the Nasdaq Stock Market under the new ticker symbol "IMNN" effective as of the opening of trading on September 21, 2022. The Company has filed an amendmen

      9/19/22 4:30:00 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

      110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that its Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian cancer has completed enrollment with 110 patients. GEN-1 is the Company's IL-12 gene-mediated immunotherapy. Topline results are expected in the second half of 2023. The OVATION 2 Study combines GEN-1 with standard-of-care neoadjuvant chemotherapy (NACT) in patients newly diagnosed with S

      9/15/22 8:30:00 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13

      LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on September 13th at 4:30 p.m. Eastern time. The presentation will available live and on-demand here. As previously announced, the conference will be held September 12-14 with in-person participation at the Lotte New York Palace Hotel. Dr. Le Goff is also available for in-person meetings at the conference. About Celsion Corporation Celsion is a fully integrated, clinical-stage biotechnol

      9/12/22 6:30:00 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLSN
    SEC Filings

    See more
    • SEC Form S-1/A filed by Celsion Corporation (Amendment)

      S-1/A - Imunon, Inc. (0000749647) (Filer)

      2/9/24 4:09:15 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celsion Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Imunon, Inc. (0000749647) (Filer)

      12/29/23 4:30:19 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-1 filed by Celsion Corporation

      S-1 - Imunon, Inc. (0000749647) (Filer)

      12/20/23 5:15:25 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLSN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Celsion Corporation (Amendment)

      SC 13G/A - Celsion CORP (0000749647) (Subject)

      2/14/22 3:17:01 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Celsion Corporation (Amendment)

      SC 13G/A - Celsion CORP (0000749647) (Subject)

      2/11/22 6:10:51 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Celsion CORP (0000749647) (Subject)

      2/1/21 3:15:37 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLSN
    Financials

    Live finance-specific insights

    See more
    • Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022

      LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, August 15, 2022 to discuss financial results for the second quarter ended June 30, 2022 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologie

      8/8/22 8:30:00 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022

      LAWRENCEVILLE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, May 16, 2022 to discuss financial results for the first quarter ended March 31, 2022 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologies fo

      5/9/22 8:30:00 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022

      LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Thursday, March 31, 2022 to discuss financial results for the year ended December 31, 2021 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologies fo

      3/24/22 9:00:00 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLSN
    Leadership Updates

    Live Leadership Updates

    See more
    • Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer

      Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Company's Board of Directors has appointed biopharmaceutical leader Corinne Le Goff, Pharm D, MBA, as President and Chief Executive Officer and Director, effective July 18, 2022. Current President and CEO Michael H. Tardugno will continue to serve as Executive Chairman of Celsion's Board of Directors. Dr. Le Goff brings decades of global healthcare leadership experience to the Company across a range of therapeutic areas i

      7/19/22 8:30:00 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Science 37® Appoints Christine Pellizzari as Chief Legal Officer

      With this important addition to its executive team, Science 37 will further advance its mission to accelerate clinical trials by enabling universal access to patients and providers Science 37, pioneer of the Decentralized Clinical Trial Operating System™ (DCT OS), today announced that Christine Pellizzari has joined the senior executive team as Chief Legal Officer. In this role, Ms. Pellizzari will use her nearly 30 years of legal expertise to manage the legal and quality functions to help advance Science 37's mission to enable universal access to clinical research for patients and providers, anywhere. This press release features multimedia. View the full release here: https://www.business

      9/1/21 7:55:00 AM ET
      $CLSN
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celsion Appoints Christine A. Pellizzari to its Board of Directors

      Brings extensive biopharmaceutical legal background to the Board Appointment increases the size of Celsion’s Board from seven to eight Directors LAWRENCEVILLE, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced the appointment of Christine A. Pellizzari to the Celsion Board of Directors, effective June 8, 2021. Ms. Pellizzari is Chief Legal Officer of Insmed Incorporated (NASDAQ: INSM), a global biopharmaceutical company dedicated to transforming the lives of patients with serious and rare diseases and brings to Celsion more than 20 years of leadership i

      6/9/21 8:00:00 AM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLSN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hazard Sebastien was granted 20,000 shares (SEC Form 4)

      4 - Imunon, Inc. (0000749647) (Issuer)

      12/11/23 4:07:24 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Hazard Sebastien claimed no ownership of stock in the company (SEC Form 3)

      3 - Imunon, Inc. (0000749647) (Issuer)

      12/11/23 4:05:23 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Braun Donald P

      4 - Imunon, Inc. (0000749647) (Issuer)

      3/21/23 4:42:32 PM ET
      $CLSN
      Biotechnology: Pharmaceutical Preparations
      Health Care